iLite® ADCP Effector FcγRIIa Assay Ready Cells are used for quantifying biological activity induced by pathway activation of therapeutic antibody drugs in an ADCP mechanism of action (MOA) assay.
The cells are based on a human T lymphocyte cell line, Jurkat (ATCC #TIB-152), and have been genetically engineered and optimized to express high levels of the low-affinity Fc receptor FcRyIIa (CD32), and the Firefly Luciferase (FL) reporter gene under the control of a proprietary chimeric promoter.
iLite® ADCP Effector FcγRIIa Assay Ready Cells are ideally matched to the iLite® ADCP target cells but can be run with any type of target cells inducing ADCP MOA.
The ATCC® TIB-152 cell line is used under a license from ATCC®
|Technology||Cell-based reporter gene assay|
|Read-out of results||Quantitative,|
|Regulatory status||Research Use Only|
Get access to scientific material, posters and more.